Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolism and PK of [14C] BI 1356 in Healthy Volunteers
NCT02183610Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2006
- Primary completion
- Sep 2006
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of linagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Comparison of individual time course profiles of [14C] radioactivity in whole blood, plasma, urine and faeces, Comparison of individual time course profiles of BI 1356 BS and its metabolite CD 1750 XX in plasma and urine and 16 more. Started Jul 2006; status: completed.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02183610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02183610.